Clinical Study
Tacrolimus Dose Modification in Hematopoietic Cell Transplant Recipients Following a Change in Therapy from Fluconazole to Voriconazole
Table 1
Patient demographic information.
| | Patient | Age
(years) | Gender | Race | Weight
(kg) | Diagnosis | Donor Type | Scr (mg/dL)
Median (range) | T. Bili (mg/dL)
Median (range) |
| | 1 | 33 | F | Caucasian | 100.6 | MDS | Matched Unrelated, Allogeneic | 0.47 (0.27–1.0) | 0.7 (0.4–0.9) | | 2 | 74 | F | Caucasian | 88.1 | AML | Matched Unrelated, Allogeneic | 0.63 (0.4–1.2) | 0.8 (0.5–1.2) | | 3 | 43 | F | Caucasian | 77.1 | AML | Matched Unrelated, Allogeneic | 0.61 (0.4–0.85) | 0.7 (0.5–1.0) | | 4 | 58 | F | Caucasian | 72.4 | MDS | Matched Unrelated, Allogeneic | 0.48 (0.36–0.75) | 1.25 (0.6–2.8) | | 5 | 54 | F | Caucasian | 71.5 | AML | Matched Related, Allogeneic | 1.23 (0.67–2.6) | 0.8 (0.4–1.3) |
|
|
Scr: serum creatinine, T. Bili: total bilirubin, MDS: myelodysplastic syndrome, AML: acute myelogenous leukemia.
|
